[go: up one dir, main page]

EP4360629A4 - PHARMACEUTICAL COMPOSITION CONTAINING LIPASE INHIBITOR FOR THE TREATMENT OR MANAGEMENT OF RNA VIRUS INFECTIONS - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING LIPASE INHIBITOR FOR THE TREATMENT OR MANAGEMENT OF RNA VIRUS INFECTIONS Download PDF

Info

Publication number
EP4360629A4
EP4360629A4 EP22828825.4A EP22828825A EP4360629A4 EP 4360629 A4 EP4360629 A4 EP 4360629A4 EP 22828825 A EP22828825 A EP 22828825A EP 4360629 A4 EP4360629 A4 EP 4360629A4
Authority
EP
European Patent Office
Prior art keywords
management
treatment
pharmaceutical composition
composition containing
rna virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22828825.4A
Other languages
German (de)
French (fr)
Other versions
EP4360629A1 (en
Inventor
Kyoung Oh Cho
Tae Il Jeon
Sun Woo Lee
Yeong Bin Baek
Hyung Jun Kwon
Hueng Sik CHOI
Sang Ik Park
Muhammad Sharif
Jeong Ah Lim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Industry Foundation of Chonnam National University
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Industry Foundation of Chonnam National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020220077063A external-priority patent/KR102871928B1/en
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB, Industry Foundation of Chonnam National University filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of EP4360629A1 publication Critical patent/EP4360629A1/en
Publication of EP4360629A4 publication Critical patent/EP4360629A4/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP22828825.4A 2021-06-25 2022-06-24 PHARMACEUTICAL COMPOSITION CONTAINING LIPASE INHIBITOR FOR THE TREATMENT OR MANAGEMENT OF RNA VIRUS INFECTIONS Pending EP4360629A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20210083385 2021-06-25
KR1020220077063A KR102871928B1 (en) 2021-06-25 2022-06-23 Pharmaceutical composition containing lipolytic enzyme inhibitors for preventing or treating RNA virus infection
PCT/KR2022/009041 WO2022270978A1 (en) 2021-06-25 2022-06-24 Pharmaceutical composition comprising lipase inhibitor for treatment or treatment of rna viral infections

Publications (2)

Publication Number Publication Date
EP4360629A1 EP4360629A1 (en) 2024-05-01
EP4360629A4 true EP4360629A4 (en) 2024-11-06

Family

ID=84544668

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22828825.4A Pending EP4360629A4 (en) 2021-06-25 2022-06-24 PHARMACEUTICAL COMPOSITION CONTAINING LIPASE INHIBITOR FOR THE TREATMENT OR MANAGEMENT OF RNA VIRUS INFECTIONS

Country Status (3)

Country Link
US (1) US20240285557A1 (en)
EP (1) EP4360629A4 (en)
WO (1) WO2022270978A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019104686A (en) * 2017-12-08 2019-06-27 キッコーマン株式会社 Anti-influenza virus agent and composition containing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130210883A1 (en) * 2010-05-21 2013-08-15 Johannes Grillari Lipase inhibitors
EP2627334B1 (en) * 2010-10-15 2015-04-29 Biocryst Pharmaceuticals, Inc. Compositions for use in the treatment of viral infections
PL3917140T3 (en) 2012-01-19 2023-12-04 Vid Scale, Inc. Method and apparatus for signaling and construction of video coding reference picture lists
US20180256623A1 (en) * 2015-09-16 2018-09-13 University Of Virginia Patent Foundation Compositions and method for regulating adipose tissue lipolysis, insulin-resistance, and hyperglycemia
KR102561804B1 (en) 2020-12-01 2023-07-31 주식회사 글로벌테크놀로지 Backlight apparatus for display, current deviation compensation method and compensation circuit of the backlight apparatus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019104686A (en) * 2017-12-08 2019-06-27 キッコーマン株式会社 Anti-influenza virus agent and composition containing the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LAUFMAN ORLY ET AL: "Viral Generated Inter-Organelle Contacts Redirect Lipid Flux for Genome Replication", CELL, ELSEVIER, AMSTERDAM NL, vol. 178, no. 2, 13 June 2019 (2019-06-13), pages 275, XP085739926, ISSN: 0092-8674, [retrieved on 20190613], DOI: 10.1016/J.CELL.2019.05.030 *
NITIN A LUNAGARIYA ET AL: "Review article: INHIBITORS OF PANCREATIC LIPASE: STATE OF THE ART AND CLINICAL PERSPECTIVES", EXCLI JOURNAL, 22 August 2014 (2014-08-22), pages 897 - 921, XP055739962, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464291/pdf/EXCLI-13-897.pdf> *
See also references of WO2022270978A1 *
TANNER JEROME E. ET AL: "The Fatty Acid Lipid Metabolism Nexus in COVID-19", VIRUSES, vol. 13, no. 1, 11 January 2021 (2021-01-11), CH, XP093206734, ISSN: 1999-4915, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826519/pdf/viruses-13-00090.pdf> DOI: 10.3390/v13010090 *

Also Published As

Publication number Publication date
EP4360629A1 (en) 2024-05-01
WO2022270978A1 (en) 2022-12-29
US20240285557A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
EP4143176A4 (en) SARS-COV-2 INHIBITORS WITH COVALENT MODIFICATIONS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
EP4157272C0 (en) Remdesivir for the treatment of viral infections
EP4175629A4 (en) TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
EP3900717C0 (en) VIDOFLUDIMUS FOR USE IN THE TREATMENT OR PREVENTION OF VIRUS DISEASES
EP4426682A4 (en) SARS-CoV-2 inhibitors for the treatment of coronavirus infections
EP4438048A4 (en) Pharmaceutical composition for the treatment or prevention of T-cell-related diseases
EP4000609A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
EP4151227A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER
EP4419504A4 (en) KDM1A inhibitors for the treatment of diseases
EP3620457A4 (en) PYRIMIDE-DERIVATIVE COMPOUND, OPTICAL ISOMER THEREOF, OR PHARMACEUTICAL SALT THEREOF AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYRO-3 RELATED DISEASES THEREOF AS ACTIVE SUBSTANCE
EP3955908C0 (en) NOVEL MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS
EP4142728C0 (en) 6&#39;-METHOXYCINCHONAN-9-OLS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
EP4125893A4 (en) TECHNOLOGIES FOR THE PREVENTION OR TREATMENT OF INFECTIONS
EP4431098A4 (en) Pharmaceutical composition for the treatment of Alport syndrome
EP4382123A4 (en) Pharmaceutical composition for the treatment of small cell lung cancer
EP4285910A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NERVE INFECTIONS WITH ELEUTHEROSIDE B AS ACTIVE INGREDIENT
EP4360629A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING LIPASE INHIBITOR FOR THE TREATMENT OR MANAGEMENT OF RNA VIRUS INFECTIONS
EP3919063A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF LYSOSOMIC STORAGE DISEASES
EP4452295A4 (en) Pharmaceutical composition for the treatment of viral infections
EP4203954A4 (en) GLUCOSIDASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS
EP4582087A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LYMPHOMAS
EP4149451A4 (en) CYSTEAMINE FOR THE TREATMENT OF SARS-COV-2 INFECTION
EP4306133A4 (en) Composition for the administration of double-stranded oligonucleotide structures using an ultrasonic nebulizer for the prevention or treatment of viral infections
EP4351546A4 (en) HOST-DIRECTED DRUG COMBINATIONS FOR THE TREATMENT OF VIRUS INFECTIONS
EP4570251A4 (en) Composition for the treatment or prevention of kidney diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20241008

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/706 20060101ALI20241001BHEP

Ipc: A61K 31/215 20060101ALI20241001BHEP

Ipc: A61P 31/14 20060101ALI20241001BHEP

Ipc: A61K 31/4245 20060101ALI20241001BHEP

Ipc: A61K 31/5375 20060101ALI20241001BHEP

Ipc: A61K 31/40 20060101ALI20241001BHEP

Ipc: A61K 31/17 20060101AFI20241001BHEP